BioNTech SE

Invus Public Equities Advisors makes majority investments in private, high growth companies. The firm also takes significant, long-term positions in public companies whose fundamentals and management they believe in. Invus focuses on investments in the stocks of small- to mid-cap companies that are trading below the firm's assessment of their intrinsic business value. The average holding period in their public equity portfolio is measured in years. Invus invests in a variety of industries, including but not limited to, consumer products and services, food, specialty retail, software, biotechnology, medical devices, healthcare products and professional services.

Parus Finance (UK) Ltd., a subsidiary of Parus Finance Holding Ltd., is a British company located in London. The firm provides investment advice. It was founded in 2012 by Fabrizio Marco Fausto Vecchioli and Edouard Vecchioli. Fabrizio Marco Fausto Vecchioli has been the CEO since then.

Seven Eight Capital’s strategy focuses on trading a wide number of liquid equity securities and futures contracts that trade on established US markets. The Firm's investment strategies are market-neutral and based on a set of methods known as statistical arbitrage. The process consists of investing in a broad portfolio of liquid securities for a short duration. Seven Eight Capital has broad discretion in making investments and will generally consist of global equity securities and other assets that may be affected by business, financial market or legal uncertainties. The Firm may invest a portion of its assets in the stocks of companies with small-to medium-sized market capitalizations and may pursue relative value strategies by taking long positions in securities believed to be undervalued and short positions in securities believed to be overvalued.

HEP seeks invests in fast-growing, market leading companies, operating in China, India, south korea and the ASEAN countries. The firm targets companies operating in the fields of financial services, healthcare, information technology, infrastructure, media, retail, telecommunications, consumer products, logistics and alternative energy. It provides financing for buyout and growth capital requirements with an investment size ranging from $10 to $50 million.

ATS Beteiligungsverwaltung is an active manager which invests in selected German companies in the biotech sector.

MIG is a private equity investment firm with a long-term outlook. The firm invests across sectors and development stages in innovative, generally medium-sized companies located primarily in Germany, Austria and Switzerland. Although they do not have sector restrictions, they favor technology-based companies and more particularly the biotechnology, healthcare and medical technology sectors. They aim to invest after thoroughly auditing the viability of potential investees, focusing on genuine innovation, high-growth market potential based on a clear customer benefit, and the entrepreneurial skills of the management team. They also look for companies with the potential to make a positive contribution to society.MIG describes their investment approach as that of a committed, entrepreneurial partner. The firm invests EUR 100 thousand and above in the form of direct equity, in startups and expansion-stage businesses. The firm may invest over several financing rounds, and investments are conditional on milestones being reached. MIG's targeted exit horizon is four to eight years.